Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Efficacy and Biodistribution of Novel AAV Capsids for CNS Gene Delivery in Non-Human Primates

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Efficacy and Biodistribution of Novel AAV Capsids for CNS Gene Delivery in Non-Human Primates

CELL & GENE | RNA | BIOLOGICS

What are the primary challenges in assessing AAV capsid biodistribution in the NHP central nervous system (CNS)?
The primary challenges include bypassing the blood-brain barrier, navigating complex CNS tissue architecture, and achieving precise quantification. Validated, sensitive analytical methods are required to accurately measure vector copy numbers and transgene expression, differentiating on-target delivery from non-target tissue biodistribution across multiple brain regions and the spinal cord.
How does neonatal AAV administration influence long-term transgene expression and immunogenicity for CNS targets?
Neonatal systemic AAV administration can influence long-term outcomes by inducing immunological tolerance to the transgene product. This strategy mitigates the risk of neutralizing antibody formation, enabling more durable expression following subsequent CNS-directed administration in gene therapy applications.
Why do AAV transduction patterns in the liver differ between species, and how does this impact CNS-directed study design?
Observed patterns of liver transduction can differ between rodent models and non-human primates. This affects predictions of vector clearance, potential liver-related safety findings, and systemic transgene expression. Accurate modeling in NHPs provides predictive data for de-risking clinical translation and correctly interpreting biodistribution data for CNS-targeted vectors.
What GxP-compliant analytical methods are used to quantify vector distribution and transgene expression in NHP CNS tissues?
Our studies operate within a GxP framework, employing a suite of validated assays. These include ddPCR for absolute vector copy number quantification, RT-qPCR for mRNA transcript analysis, ELISA or MSD for protein quantification, and advanced Histology techniques such as immunohistochemistry (IHC) and in situ hybridization (ISH) for spatial analysis of transgene expression at the cellular level.

Translating AAV gene therapy programs for CNS disorders from small animal models to human clinical trials requires rigorous evaluation in non-human primates (NHPs). NHP models provide the most predictive data on capsid tropism, biodistribution, efficacy, and potential immunogenicity. This page outlines Franklin Biolabs’ approach to executing these complex pharmacology studies, focusing on quantitative analytics and strategic study designs that generate IND-enabling data.

Defining Capsid Performance in a Predictive Translational Model

The efficacy of a CNS-directed AAV therapy is determined by the capsid’s ability to transduce target cells while minimizing uptake in other tissues. While initial capsid screening often occurs in rodent models, species-specific differences in cellular receptors and immune responses necessitate validation in NHPs. Our pharmacology and efficacy studies are designed to provide a definitive assessment of vector performance before committing to a final clinical candidate.

This process begins with advanced capsid engineering and selection, a key component of any successful AAV program.

com/resource/vector-ready-where-aav-projects-begin-and-how-they-succeed/).

A digital rendering of a DNA double helix on a dark blue background with floating particles.

A stylized, 3D rendering of a DNA double helix in light blue and white, set against a soft-focus, light gray background.

Strategic Approaches to De-Risking CNS Gene Therapy

A successful NHP study accounts for complex biological variables that can influence clinical outcomes.

  • Immunological Tolerance Induction: Pre-existing or induced immunity to the AAV capsid or transgene product can neutralize therapeutic efficacy. Insights from studies like PMID: 26022732 show that early-life, systemic vector administration can induce tolerance, creating a favorable immunological profile for subsequent CNS-directed therapies.

  • Predictive Biodistribution Modeling: Non-target tissue biodistribution, particularly in the liver, can impact both safety and the available vector dose for the CNS. As research in PMID: 21778099 highlights, liver transduction patterns differ significantly between species. NHP studies provide the only reliable data for predicting human hepatic uptake and its downstream consequences.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

IND-Enabling Pharmacology and Efficacy Studies

Our >100,000 sq ft GxP-compliant facility is equipped to execute comprehensive NHP studies that form the core of an 18-24 month IND-enabling program. These studies deliver high-resolution pharmacology validating complex biologicals by integrating in-life observations with extensive post-mortem analytics to build a complete data package.

Study Component Analytical Methods Key Deliverables
Vector Biodistribution ddPCR, qPCR Vector genome copy number per cell in CNS & peripheral tissues.
Transgene Expression RT-qPCR, IHC, ISH, ELISA mRNA and protein expression levels, cellular localization.
Pharmacodynamic Efficacy Biomarker Analysis, Histology Target engagement verification, downstream biological effects.
Immunogenicity NAb Assays, ELISpot Anti-capsid and anti-transgene antibody titers and T-cell responses.

Since 2019, programs supported by our scientific leadership have achieved a 100% IND success rate. Franklin Biolabs, launched in 2024, continues this legacy of scientific and regulatory excellence.

All NHP studies are conducted in strict compliance with USDA regulations and AAALAC International accreditation standards. Our protocols are designed around the 3Rs principles (Replacement, Reduction, and Refinement) to ensure the highest standards of ethical and humane animal care.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities